Concepedia

Publication | Open Access

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

DOIFull Paper Access

85

Citations

28

References

2014

Year

Dilip Nathwani, Oliver A. Cornely, A. K. van Engen, O. Odufowora-Sita, P. Retsa, Isaac Odeyemi
Journal of Antimicrobial Chemotherapy

Abstract

Fidaxomicin is cost-effective in patients with severe CDI and in patients with a first CDI recurrence versus vancomycin.

References

YearCitations

Page 1